Botulinum toxin type A for treating upper or lower limb focal spasticity associated with stroke [ID768]
In development
Reference number: GID-TAG499
Expected publication date: TBC
The Department of Health has asked us to carry out a Multiple Technology Appraisal of botulinum toxin type A preparations (Botox, Dysport, and Xeomin) within their marketing authorisations for treating upper or lower limb focal spasticity associated with stroke.
This appraisal involves a number of companies and as the appraisal will be covering the treatment for upper or lower focal spasticity there are a broad range of licenses. NICE therefore has to ensure that all products will be licensed at the appropriate point in the appraisal. Taking all of these points into account and in order to undertake this appraisal efficiently whilst providing the best value to the NHS the appraisal will be rescheduled.
The revised timelines will be available in due course.